Analysts Set HilleVax, Inc. (NASDAQ:HLVX) PT at $9.20

HilleVax, Inc. (NASDAQ:HLVX) has been given an average rating of “Hold” by the six analysts that are currently covering the firm, MarketBeat reports. Six analysts have rated the stock with a hold recommendation. The average 1-year price objective among brokers that have issued a report on the stock in the last year is $9.20.

HLVX has been the topic of several recent analyst reports. Stifel Nicolaus downgraded shares of HilleVax from a “buy” rating to a “hold” rating and reduced their target price for the company from $34.00 to $3.00 in a research note on Tuesday, July 9th. JPMorgan Chase & Co. restated a “neutral” rating and set a $5.00 price target (down from $24.00) on shares of HilleVax in a research report on Monday, July 8th. Leerink Partnrs cut HilleVax from a “strong-buy” rating to a “hold” rating in a report on Tuesday, July 9th. Guggenheim lowered HilleVax from a “buy” rating to a “neutral” rating in a research note on Monday, July 8th. Finally, SVB Leerink lowered HilleVax from an “outperform” rating to a “market perform” rating and lowered their target price for the company from $28.00 to $2.00 in a research note on Tuesday, July 9th.

Insiders Place Their Bets

In other HilleVax news, Director Aditya Kohli sold 6,000 shares of the company’s stock in a transaction on Wednesday, May 22nd. The stock was sold at an average price of $14.73, for a total transaction of $88,380.00. Following the transaction, the director now owns 764,878 shares of the company’s stock, valued at approximately $11,266,652.94. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Company insiders own 71.10% of the company’s stock.

Institutional Trading of HilleVax

Institutional investors and hedge funds have recently made changes to their positions in the business. EntryPoint Capital LLC bought a new stake in shares of HilleVax during the 1st quarter valued at $80,000. SG Americas Securities LLC bought a new stake in shares of HilleVax during the 4th quarter valued at $139,000. Tidal Investments LLC bought a new stake in shares of HilleVax during the 1st quarter valued at $207,000. abrdn plc bought a new stake in shares of HilleVax in the 4th quarter valued at $433,000. Finally, Swiss National Bank increased its position in shares of HilleVax by 22.4% in the 4th quarter. Swiss National Bank now owns 38,200 shares of the company’s stock valued at $613,000 after buying an additional 7,000 shares in the last quarter. Institutional investors own 86.42% of the company’s stock.

HilleVax Stock Down 3.6 %

Shares of HLVX stock opened at $1.60 on Friday. The stock has a market cap of $79.55 million, a P/E ratio of -0.48 and a beta of 0.80. HilleVax has a one year low of $1.55 and a one year high of $20.22. The stock has a fifty day moving average price of $7.79 and a 200 day moving average price of $12.51. The company has a debt-to-equity ratio of 0.11, a current ratio of 10.92 and a quick ratio of 10.92.

HilleVax (NASDAQ:HLVX) last issued its earnings results on Thursday, May 9th. The company reported ($0.97) EPS for the quarter, missing the consensus estimate of ($0.84) by ($0.13). Analysts predict that HilleVax will post -2.58 earnings per share for the current year.

HilleVax Company Profile

HilleVax, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. It develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company was formerly known as MokshaCo, Inc and changed its name to HilleVax, Inc in February 2021.